Janux Therapeutics Inc. (JANX)
| Bid | 30.2 |
| Market Cap | 1.88B |
| Revenue (ttm) | 11.01M |
| Net Income (ttm) | -71.75M |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -24.81 |
| Forward PE | -18.85 |
| Analyst | Buy |
| Ask | 35.09 |
| Volume | 581,551 |
| Avg. Volume (20D) | 966,756 |
| Open | 30.14 |
| Previous Close | 29.94 |
| Day's Range | 30.14 - 32.00 |
| 52-Week Range | 28.92 - 71.71 |
| Beta | 3.22 |
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ...
Analyst Forecast
According to 8 analyst ratings, the average rating for JANX stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 120.40% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 DataJanux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRAC...
2 months ago · seekingalpha.com
Best-Performing Stocks Of 2024Best-Performing Stocks Of 2024